Butterfly Q1 Revenue Reaches $26.5M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Reports Q1 revenue $26.5M, consensus $25.74M. Joseph DeVivo, CEO, commented, "Butterfly opened the year with another strong quarter, coming in above consensus with 25% revenue growth and continued gross margin improvement. We are executing with discipline while continuing to invest in the vast opportunity ahead. Our business is starting to come together around three growth engines. Point-of-care ultrasound is scaling globally. Home & Community Care is extending that capability into the patient environment. And Butterfly Embedded is expanding our technology beyond medical ultrasound into new modalities. These are not separate opportunities. They are all part of the same Butterfly platform, a single system that is beginning to work together and compound over time. We are still early, but the direction is clear, and we are building with focus and discipline to drive long-term growth."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFLY
Wall Street analysts forecast BFLY stock price to fall
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.680
Low
4.00
Averages
4.25
High
4.50
Current: 5.680
Low
4.00
Averages
4.25
High
4.50
About BFLY
Butterfly Network, Inc. is a healthcare company focused on medical imaging with its Ultrasound-on-Chip semiconductor technology and ultrasound software solutions. The Company's solution, leveraging its Ultrasound-on-Chip technology, enables the practical application of ultrasound information into the clinical workflow. Its product portfolio includes a combination of hardware and software, including Butterfly iQ3, Butterfly iQ+, Butterfly iQ+ Bladder, and Butterfly iQ+ Vet devices, software subscriptions, and professional services. It offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials as well as its ScanLab education-only app, formal education programs through its Butterfly Academy software and Butterfly Certified courses, as well as professional services for large scale deployments. Its devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Butterfly Network Appoints New Board Member
- New Board Member: Butterfly Network announced the appointment of Caroll H. Neubauer to its Board of Directors effective May 18, 2026, where he will serve on the Compensation and Technology Committees, bringing valuable strategic guidance from his extensive background in the medical device industry.
- Rich Industry Experience: Neubauer spent nearly three decades at B. Braun, where he grew annual revenue from approximately $1 billion to over $8 billion, showcasing his exceptional capabilities in business expansion and market development, which are expected to help Butterfly gain a competitive edge in the rapidly evolving healthcare market.
- Healthcare Industry Influence: As a board member of AdvaMed for over 15 years, Neubauer played a key role in repealing the U.S. medical device tax in 2019 and received the Lifetime Achievement Award in 2024, indicating his significant impact on healthcare policy, which may support Butterfly's advocacy efforts.
- Technological Platform Advantage: Neubauer emphasized the importance of Butterfly's technology platform in accelerating profitability and pursuing diverse growth strategies, suggesting that his involvement will further drive innovation and market expansion in the medical imaging sector.
See More
Butterfly Network Reports Strong Q1 2026 Earnings with FDA Milestone
- Strong Financial Performance: Butterfly Network reported Q1 2026 revenue of $26.5 million, reflecting a 25% year-over-year growth with a gross margin of 69%, indicating robust growth in both U.S. and international markets, thereby reinforcing its leadership in the point-of-care ultrasound sector.
- Regulatory Milestone: The company achieved FDA clearance for a blind sweep AI tool that can determine fetal age in just two minutes, which is expected to unlock new partnerships with health ministries in developing countries, facilitating business expansion.
- Commercial Plan Update: The company anticipates signing its first commercial agreement for home care in the first half of 2026 and plans to begin training nurses in the third quarter, marking a significant step in its strategy to penetrate the home care market, with expectations for substantial expansion by 2027.
- Growth Drivers: The CFO noted double-digit growth in both core and embedded businesses, with embedded revenue soaring 147% year-over-year, primarily driven by the successful partnership with Midjourney, which is expected to continue enhancing overall company performance.
See More
Butterfly Network Q1 Results Exceed Expectations Despite Stock Drop
- Strong Q1 Performance: Butterfly Network reported Q1 revenue of $26.5 million, a 25% year-over-year increase, yet the stock fell about 8%, indicating investor concerns over ongoing losses.
- Adjusted EBITDA Loss: The company posted an adjusted EBITDA loss of $6.1 million, which, while reduced, failed to bolster investor confidence in future profitability, contributing to downward pressure on the stock.
- Cash Position: At the end of the quarter, Butterfly Network held $138 million in cash, providing a financial cushion for future operations and growth, although market sentiment regarding profitability remains cautious.
- Future Guidance: The company provided Q2 revenue guidance of $27 million to $31 million, aligning with consensus expectations, but lacking upside momentum; however, it reaffirmed its FY26 outlook, indicating steady progress towards profitability.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is developing a novel intoxication detection platform that leverages artificial intelligence and voice analysis to identify impairment from multiple substances in real-time, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting a strong demand for efficient, scalable, and non-invasive solutions, particularly in industries such as mining, aviation, and transportation.
- Data-Driven Approach: MindBio's technology is built on clinical trials and large-scale data analysis involving over 50 million data points, demonstrating high accuracy in intoxication detection, which enhances workplace safety by providing real-time assessments for both consumers and enterprises.
- Industry Impact: As AI-driven diagnostic technologies continue to gain traction, MindBio's voice detection platform is poised to play a pivotal role in improving road safety, workplace compliance, and public health, driving the industry towards more efficient detection technologies.
See More
MindBio Launches AI Voice Detection Technology for Intoxication
- Technological Innovation: MindBio Therapeutics is advancing a novel system that leverages artificial intelligence and voice analysis to detect intoxication in real-time from short speech samples, addressing critical gaps in traditional detection methods and potentially transforming public safety and health management.
- Market Potential: The company targets a total addressable market of approximately $47 billion in workplace safety and substance testing, reflecting the urgent demand for efficient, scalable, and noninvasive detection solutions across industries such as mining, aviation, and transportation.
- Multisubstance Detection Capability: MindBio's technology can detect intoxication from multiple substances through speech pattern analysis, representing a significant advancement over traditional single-substance testing methods, which could enhance decision-making and improve safety outcomes.
- First-Mover Advantage: MindBio's early positioning in the voice-based diagnostics field, supported by clinical trials and analysis of over 50 million data points, may provide a competitive edge that is difficult for rivals to replicate, solidifying the company's leadership in the rapidly evolving AI-driven diagnostics market.
See More
Butterfly Network Appoints New Board Member
- New Board Member: Butterfly Network announced the appointment of Caroll H. Neubauer to its Board of Directors effective May 18, 2026, where he will serve on the Compensation and Technology Committees, bringing valuable strategic guidance from his extensive background in the medical device industry.
- Rich Industry Experience: Neubauer spent nearly three decades at B. Braun, where he grew annual revenue from approximately $1 billion to over $8 billion, showcasing his exceptional capabilities in business expansion and market development, which are expected to help Butterfly gain a competitive edge in the rapidly evolving healthcare market.
- Healthcare Industry Influence: As a board member of AdvaMed for over 15 years, Neubauer played a key role in repealing the U.S. medical device tax in 2019 and received the Lifetime Achievement Award in 2024, indicating his significant impact on healthcare policy, which may support Butterfly's advocacy efforts.
- Technological Platform Advantage: Neubauer emphasized the importance of Butterfly's technology platform in accelerating profitability and pursuing diverse growth strategies, suggesting that his involvement will further drive innovation and market expansion in the medical imaging sector.
See More
Butterfly Network Reports Strong Q1 2026 Earnings with FDA Milestone
- Strong Financial Performance: Butterfly Network reported Q1 2026 revenue of $26.5 million, reflecting a 25% year-over-year growth with a gross margin of 69%, indicating robust growth in both U.S. and international markets, thereby reinforcing its leadership in the point-of-care ultrasound sector.
- Regulatory Milestone: The company achieved FDA clearance for a blind sweep AI tool that can determine fetal age in just two minutes, which is expected to unlock new partnerships with health ministries in developing countries, facilitating business expansion.
- Commercial Plan Update: The company anticipates signing its first commercial agreement for home care in the first half of 2026 and plans to begin training nurses in the third quarter, marking a significant step in its strategy to penetrate the home care market, with expectations for substantial expansion by 2027.
- Growth Drivers: The CFO noted double-digit growth in both core and embedded businesses, with embedded revenue soaring 147% year-over-year, primarily driven by the successful partnership with Midjourney, which is expected to continue enhancing overall company performance.
See More
Butterfly Network Q1 Results Exceed Expectations Despite Stock Drop
- Strong Q1 Performance: Butterfly Network reported Q1 revenue of $26.5 million, a 25% year-over-year increase, yet the stock fell about 8%, indicating investor concerns over ongoing losses.
- Adjusted EBITDA Loss: The company posted an adjusted EBITDA loss of $6.1 million, which, while reduced, failed to bolster investor confidence in future profitability, contributing to downward pressure on the stock.
- Cash Position: At the end of the quarter, Butterfly Network held $138 million in cash, providing a financial cushion for future operations and growth, although market sentiment regarding profitability remains cautious.
- Future Guidance: The company provided Q2 revenue guidance of $27 million to $31 million, aligning with consensus expectations, but lacking upside momentum; however, it reaffirmed its FY26 outlook, indicating steady progress towards profitability.
See More
